The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2022 | Pros and cons of autologous and allogeneic CAR-Ts
Michael Schmitt, MD, PhD, University Clinic Heidelberg, Heidelberg, Germany, compares the use of autologous and allogeneic chimeric antigen receptor T-cell (CAR-T) therapy. In current clinical practice, patients are treated with autologous CAR-Ts. However, the whole process of making an autologous CAR-T product can take up to eight weeks for a single patient. Off-the-shelf allogeneic CAR-Ts would overcome this issue as a single healthy donor can be used to produce CAR-Ts for a large number of patients, which can be transfused directly after lymphodepleting chemotherapy. Prof. Schmitt explains that since allogeneic CAR-Ts can be rejected by the recipient’s immune system, they must be modified genetically. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
